ストックスクリーナーアプリを入手
0.65
36.89%
-0.38
前日終値:
$1.03
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
-
当期純損益:
$-22.01M
株価収益率:
-0.00761
EPS:
-85.4
ネットキャッシュフロー:
$-18.31M
1週間 パフォーマンス:
-36.89%
1か月 パフォーマンス:
-48.00%
6か月 パフォーマンス:
+22.64%
1年 パフォーマンス:
-88.61%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$1.50
Vaccinex Inc Stock (VCNX) Company Profile
Compare VCNX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.00 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.88 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.07 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
711.36 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.13 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.24 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-09-23 | ダウングレード | BTIG Research | Buy → Neutral |
| 2018-09-04 | 開始されました | Ladenburg Thalmann | Buy |
Vaccinex Inc (VCNX) 最新ニュース
VCNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight - The Malaysian Reserve
MSN Money - MSN
Vaccinex (VCNX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vaccinex Inc (VCNX) Is Going Wild: Tiny Biotech, Massive Risk – Is It Worth the Hype? - AD HOC NEWS
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX) - Defense World
Micro Cap Biotech Secures $60M to Advance Alzheimer’s Treatment, Shares Surge - The Globe and Mail
Vaccinex secures $60 million funding for Alzheimer’s drug development By Investing.com - Investing.com Australia
Vaccinex announces $60M revenue sharing agreement with PDV - MSN
Vaccinex Secures $60 Mln To Advance Enlarged Phase 2b Alzheimer's Trial - Nasdaq
Vaccinex secures $60 million funding for Alzheimer’s drug development - Investing.com
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment - Quiver Quantitative
Net Asset Value(s) - The Manila Times
Biometric Identification / Cybersecurity SaaS Solutions Provider BIO-key Presents at DealFlow Discovery Investor Conference Jan. 28 & 29 in Atlantic City, NJ - The Manila Times
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - The Manila Times
MBAK Energy Solutions, Inc. (OTC:MBAK) partners with Carbon Zero Mobility in Kenya and the University of Michigan on Charger Design - The Manila Times
Outpace Wins 144+ SEO Awards, Establishing Itself as one of the Best SEO Agencies in the US - The Manila Times
Renewal Fuels (RNWF) & Its Subsidiary American Fusion Highlight Near-Term Commercial Fusion Strategy, Underscoring Key Distinctions Between Deployable Energy Infrastructure & Experimental Fusion Programs - The Manila Times
SunPower Q3’25 10Q Report Filed - The Manila Times
OSS Receives Follow-On Production Order from Safran Federal Systems - The Manila Times
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - The Manila Times
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months - The Manila Times
ZenaTech Closes Acquisition of Vara 3D, a Utah-Based Surveying and Mapping Firm Expanding Drone-as-a-Service to the High-Growth Solar Infrastructure Market - The Manila Times
Getty Realty Corp. To Report Fourth Quarter 2025 Financial Results - The Manila Times
dLocal completes transition to a majority independent Board with appointments of Paco Ybarra and Nelson Mattos - The Manila Times
Cassava Announces Agreement to Settle Securities Class Action Litigation - The Manila Times
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - The Manila Times
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th - The Manila Times
Genius Group Acquires Lighthouse Studios, to Launch Genius Studios. - The Manila Times
Nuvini Announces Strategic Restructuring of Earnout Liabilities with 36% Reduction - The Manila Times
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors - The Manila Times
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 - The Manila Times
Safe Harbor Expands Consulting and Managed Services Platform Through Talent-Led Strategic Transaction - The Manila Times
Ronald P. Mathison and MATCO Investments Ltd. File Early Warning Report Regarding Calfrac Well Services Ltd. - The Manila Times
Willis Lease Finance Corporation Announces Closing of $392,900,000 in Fixed Rate Notes - The Manila Times
Director/PDMR Shareholding - The Manila Times
Baiya International Group Inc. Announce Reverse Split Record Date - The Manila Times
Aspocomp Group Plc: Notification of management’s transactionTerhi Launis (acquisition) - The Manila Times
Vaccinex, Inc. Announces $60 million Agreement to Finance - GlobeNewswire
Analyzing Whitehawk Therapeutics (NASDAQ:WHWK) & Vaccinex (NASDAQ:VCNX) - Defense World
Head to Head Contrast: ObsEva (NASDAQ:OBSV) & Vaccinex (NASDAQ:VCNX) - Defense World
NeurAxis, Inc. (NRXS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
AIM ImmunoTech Inc. (AIMI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Revenue per share of Vaccinex, Inc. – OTC:VCNX - TradingView
Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World
Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World
Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
What sets apart Novavax option from other COVID-19 vaccines - American Medical Association
Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World
Vaccinex Inc (VCNX) 財務データ
収益
当期純利益
現金流量
EPS
1.42%
0.24%
大文字化:
|
ボリューム (24 時間):